Bank of America Forecasts Strong Price Appreciation for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by research analysts at Bank of America from $908.00 to $1,030.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s price objective would suggest a potential upside of 11.00% from the company’s previous close.

Several other brokerages have also commented on REGN. Raymond James Financial lifted their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. increased their target price on shares of Regeneron Pharmaceuticals from $900.00 to $950.00 and gave the company an “overweight” rating in a research report on Tuesday, October 6th. Citigroup raised their target price on Regeneron Pharmaceuticals from $740.00 to $825.00 and gave the company a “neutral” rating in a research note on Friday. Sanford C. Bernstein upped their price target on Regeneron Pharmaceuticals from $753.00 to $756.00 and gave the company a “market perform” rating in a report on Friday, August 14th. Finally, Truist Financial increased their target price on Regeneron Pharmaceuticals from $772.00 to $780.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $872.00.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $927.89 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.66 and a current ratio of 4.06. The company’s fifty day moving average is $793.30 and its two-hundred day moving average is $738.05. The company has a market capitalization of $95.54 billion, a P/E ratio of 20.49, a PEG ratio of 1.57 and a beta of 0.10. Regeneron Pharmaceuticals has a 1 year low of $591.52 and a 1 year high of $935.35.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating analysts’ consensus estimates of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The company’s revenue for the quarter was up 36.3% compared to the same quarter last year. During the same period in the previous year, the business earned $11.83 earnings per share. Analysts forecast that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 31.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director directly owned 603 shares in the company, valued at $512,550. This represents a 39.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of REGN. Boston Trust Walden Corp increased its position in Regeneron Pharmaceuticals by 794.1% during the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock valued at $8,088,000 after purchasing an additional 9,474 shares during the period. Chicago Partners Investment Group LLC increased its stake in Regeneron Pharmaceuticals by 29.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after acquiring an additional 656 shares during the last quarter. Covestor Ltd raised its position in Regeneron Pharmaceuticals by 31.5% during the third quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 41 shares in the last quarter. Compass Financial Management LLC raised its position in Regeneron Pharmaceuticals by 4,526.2% in the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock worth $2,280,000 after purchasing an additional 2,942 shares during the period. Finally, Pzena Investment Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the third quarter worth $310,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.